Table 5.

Frequency of most commonly observed AEs (≥5%) by dosage arm

Erlotinib dose
AE25 mg50 mg100 mg
Events, nParticipants (N = 15)Events, nParticipants (N = 15)Events, nParticipants (N = 15)
Diarrhea44 (27%)54 (27%)65 (33%)
Dryness/itchiness (includes skin, eyes, and mouth)97 (47%)87 (47%)107 (47%)
Fatigue11 (7%)0033 (20%)
Flatulence0021 (7%)00
Nausea22 (13%)22 (13%)00
Oral sores0022 (13%)11 (7%)
Rash55 (33%)76 (40%)1412 (80%)